Top Stories
DAX-044 is an investigational IL-12 antibody–cytokine fusion designed to stimulate immune activity in solid tumours while limiting toxicity.
After Patrik Jonsson's departure, Lilly's US and international businesses will be combined under one umbrella, dubbed Lilly Global Markets, which will be led by Ilya Yuffa.
The two will combine molecular tumour profiling with existing clinical data to explore whether previously studied drugs could benefit different cancer populations.
The drugmaker is spending up to $125 million to gain Igalmi, a sublingual film approved to treat agitation associated with schizophrenia or bipolar disorder, as well as experimental at-home treatment BXCL501.
The ruling found that Novo failed to establish immediate commercial harm and had itself employed similar promotional tactics.
Conference News
MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:Sensorion (FR001401A9Z0 – ALSEN) (“the Company”), a pioneering clinical-stage biotechnology company that develops novel therap...
Record 64 Research Presentations Highlight Hengrui's Oncology R&D Strength and Growing International ReachMADRID and SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- The European Society for Medical Oncology (...
Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung c...
FirstWord spoke with Washington University neurologist Salim Chahin about detailed Phase III data for Novartis' remibrutinib, and what they suggest about the use of this and other BTK inhibitors in MS.
On the heels of positive data from Merck & Co. and Kelun-Biotech's Phase III OptiTROP-Lung06 study, FirstWord spoke with Christine Lovly, division chief of thoracic medical oncology at City of Hope Cancer Center, to discuss the potential role of sac-TMT in PD-L1–negative patients with locally ad
